Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01666080 · ClinicalTrials.gov registry record · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
A NA study of Hemoglobinopathies and Immunodeficiencies, sponsored by Masonic Cancer Center, University of Minnesota.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT01666080 is a NA study of Hemoglobinopathies and Immunodeficiencies that is actively recruiting participants, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 30 participants, below the 1,802-participant average among 17 other Hemoglobinopathies trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01666080, a NA study of Hemoglobinopathies and Immunodeficiencies, is actively recruiting participants, sponsored by Masonic Cancer Center, University of Minnesota.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a treatment guideline for a second or greater allogeneic hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) in patients with non-malignant or malignant diseases. This regimen, consisting of busulfan, fludarabine, and low dose total body irradiation (TBI), is designed to promote engraftment in patients who failed to achieve an acceptable level of donor-derived engraftment following a previous allogeneic HCT.
Conditions Studied
Interventions
- DRUG Fludarabine
- DRUG Busulfan
- RADIATION Total body irradiation
- BIOLOGICAL Stem cell transplant
- DRUG Keppra
Study Locations (1)
Minnesota
- Masonic Cancer Center, University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2012-08 |
| Est. Completion | 2027-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01666080
The ClinicalTrials.gov registry entry for NCT01666080 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,802-participant average among 17 other Hemoglobinopathies trials with a reported enrollment target (98% lower). The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Hemoglobinopathies appearing as the primary indexed condition, and to 5 interventions - of which Fludarabine is the first listed.
NCT01666080 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT01666080 about?
NCT01666080 is a clinical study titled "Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)". This is a treatment guideline for a second or greater allogeneic hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) in patients with non-malignant or malignant diseases. This regimen, consisting of busulfan, fludarabine, and low dose total body irradiation (TBI), ...
What is the current status of trial NCT01666080?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2012-08. Estimated completion is 2027-06.
What conditions does trial NCT01666080 study?
This clinical trial studies the following conditions: Hemoglobinopathies, Immunodeficiencies, Hematologic Disorders.
What interventions are being tested in trial NCT01666080?
The interventions under investigation include: Fludarabine (DRUG), Busulfan (DRUG), Total body irradiation (RADIATION), Stem cell transplant (BIOLOGICAL), Keppra (DRUG).
Who is sponsoring clinical trial NCT01666080?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01666080 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemoglobinopathies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion
ACTIVE NOT RECRUITING · NA
-
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
RECRUITING · Phase 1
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
-
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
RECRUITING · Phase 1
-
Study of the Role of Genetic Modifiers in Hemoglobinopathies
RECRUITING
-
Discarded Bone Marrow for Hematology Research
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.